CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 95 enrolled
Drug / intervention
Terbutaline sulphate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02322788
NCT02322788Phase 3Completed

A Randomised, Double-blind, Double-dummy, Multi-site, Phase III, Single Dose, 4-way Cross-over Pharmacodynamic Study Evaluating the Efficacy of Bricanyl Turbuhaler M3 Compared to Bricanyl Turbuhaler M2 by Studying the Protective Effect on Methacholine Induced Bronchoconstriction in Patients With Stable, Mild to Moderate Asthma

AstraZeneca·interventional·Posted Dec 23, 2014·Updated Jan 13, 2017

In Brief

A Phase 3 clinical trial evaluating Terbutaline sulphate and Placebo for terbutaline sulphate for Asthma. Completed, enrolled 95 participants across 4 sites in 3 countries.

Detailed Summary

A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M2 by studying the protective effect on methacholine induced bronchoconstriction in patients with stable, mild to moderate asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada, Netherlands, Sweden
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 23, 2014
Enrollment StartMar 1, 2015
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.5 years ago

Interventions

Terbutaline sulphatedrug

Bricanyl Turbuhaler M2

Terbutaline sulphatedrug

Bricanyl Turbuhaler M3

Placebo for terbutaline sulphatedrug

Placebo Turbuhaler M2

Placebo for terbutaline sulphatedrug

Placebo Turbuhaler M3